Business Context and Reporting Period
Company: Standard BioTools Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 27, 2024
Reporting Period: Event date August 27, 2024; Plan term through August 4, 2026.
This filing reports the approval of the "2024 Change of Control and Severance Plan" by the Human Capital Committee of the Board of Directors. The plan applies to the executive leadership team, excluding the Chief Executive Officer, who remains under the 2023 Severance Plan.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on executive compensation arrangements and severance benefits.
Material Changes
The primary material change is the implementation of the 2024 Severance Plan, which supersedes prior severance and change-in-control benefits for specific executives. The following individuals have entered into Participation Agreements under this new plan:
- Hanjoon Alex Kim (Chief Operating Officer)
- David King, Ph.D. (Senior Vice President of Global Research and Development)
- Agnieszka Gallagher (Senior Vice President and Chief Legal Officer)
- Mona Abou-Sayed (Senior Vice President of Standard BioTools Business System)
- Jeremy Davis (Chief Commercial Officer)
- Anders Davas (Senior Vice President of Global Operations)
- Betsy Jensen (Chief Human Resources Officer)
- Sean Mackay (Chief Business Officer)
Guidance, Outlook, and Plan Details
The filing details the financial contingencies triggered by termination of employment under two scenarios:
1. Termination Outside the Change of Control Period
If terminated without Cause (or due to death/disability) outside the window of three months before to 12 months after a Change of Control:
- Severance: 100% of annual base salary paid over 12 months.
- Bonus: Pro-rated lump-sum of annual target bonus.
- Health: Reimbursement for up to 12 months.
- Equity: 100% vesting acceleration of unvested awards (performance awards vest at target levels).
- Outplacement: Reasonable services provided.
2. Termination Within the Change of Control Period
If terminated without Cause or for Good Reason within the Change of Control Period:
- Severance: Lump-sum payment totaling 150% of the sum of (x) annual base salary and (y) the greater of the annual target cash incentive or the average of actual cash incentives paid over the prior three fiscal years.
- Bonus: Pro-rated lump-sum of annual target bonus (greater of pre-termination or pre-Change of Control).
- Health: Reimbursement for up to 18 months.
- Equity: 100% vesting acceleration of unvested awards (performance awards vest at target levels).
Investor Verification Checklist
- Verify the specific definitions of "Cause," "Good Reason," and "Change of Control" in the full text of Exhibit 10.1.
- Confirm the total potential liability exposure by calculating the 150% severance multiplier against current executive compensation packages.
- Review the status of the CEO's separate 2023 Severance Plan to understand the full scope of executive retention costs.
- Assess the impact of the 100% equity vesting acceleration on future dilution and share-based compensation expenses.